Long Ideas - In the latter half of 2012, shares of Illumina (NASDAQ:ILMN) saw increased volatility, owing to the twin combination of takeover speculation regarding Roche (OTC:RHHBY), as … Continue Reading
Read NowLong Ideas - On Friday, February 1st, a report out from research firm IPD Analytics took nearly 22% out of Keryx Biopharmaceuticals (KERX) by questioning the novelty and … Continue Reading
Read NowMost Popular - The event of the week? Phase III data for Zerenex, Keryx Biopharmaceutical’s phosphate binder, were released on Monday, with compelling results. PropThink has been covering … Continue Reading
Read NowMost Popular - Shares of Ampio Pharmaceuticals (AMPE) were on a tear in the past four weeks, climbing from $3.39 at the end of December to a recent … Continue Reading
Read NowLong Ideas - Transition Therapeutics (TTHI) is mostly known for its Alzheimer’s disease (AD) treatment candidate, ELND005, however partner Elan Corp. (ELN) is currently focused on advancing the … Continue Reading
Read NowLong Ideas - The highlight of our week was Allergan’s ~$1B buyout of MAP Pharmaceuticals, a company that we recommended in early January. The acquisition came at a … Continue Reading
Read NowLong Ideas - Earlier this week I had the pleasure of speaking with Alan Shortall, President and CEO of Unilife (NASDAQ:UNIS), about the company’s short and long-term prospects. … Continue Reading
Read Now